DoD Lung Cancer, Idea Development Award | W81XWH 22 LCRP IDA

FAQs: DoD Lung Cancer Research Program (LCRP) Idea Development Award (FY22)

1) What is the purpose of the LCRP Idea Development Award (FY22)?

The FY22 LCRP Idea Development Award is intended to fund early-stage, conceptually new lung cancer research ideas that are not yet fully developed but could generate compelling initial data and open entirely new directions for the field. The program is aimed at high-risk, high-reward projects that may be too exploratory for other mechanisms but could realistically lead to critical discoveries or major advances that help reduce deaths and suffering from lung cancer.

2) What types of projects does this award mechanism prioritize?

This mechanism prioritizes high-risk, high-reward lung cancer projects that introduce innovation and have a credible path to major impact. The opportunity is designed for ideas that could shift the field rather than projects that simply extend existing work in an incremental way.

3) Are incremental or extension-of-prior-work proposals a good fit?

No. Even if scientifically strong, proposals that read as incremental or that lack clear, high-impact potential are considered outside the intent of this mechanism. Reviewers expect applicants to explain plainly what is truly new about the approach and why the results could matter in a big way.

4) What does "innovation" mean in this funding opportunity?

Innovation is described as introducing a fresh paradigm, challenging existing assumptions, or approaching a known problem from an unusually creative angle. The goal is to move beyond straightforward extensions of prior research and to propose something conceptually new.

5) What does "impact" mean for this award?

Impact means the project should have a credible pathway to producing results that could meaningfully shift lung cancer research and, ultimately, patient outcomes. A direct clinical deliverable does not have to be immediate, but the applicant should convincingly describe how the work could lead to major advances.

6) Is a hypothesis required, and what standard is expected?

Yes. Applications are expected to be grounded in a clear, well-constructed, and testable hypothesis supported by strong scientific rationale.

7) Is preliminary data required even though this is an early-stage idea award?

Yes. Although the program supports early-stage ideas, it still requires preliminary data to demonstrate feasibility of the hypothesis and the proposed approach.

8) Do the preliminary data have to be from lung cancer research specifically?

No. The preliminary data do not have to come from lung cancer specifically. Feasibility evidence from related systems, models, technologies, or comparable diseases may be acceptable, as long as the application clearly explains why those data support the proposed lung cancer work.

9) Are projects focused only on mesothelioma allowed?

No. Projects focused only on mesothelioma are explicitly not allowed under this opportunity.

10) Is there a dedicated category for early-career investigators?

Yes. The opportunity includes a dedicated New Investigator category intended to support early-career scientists.

11) Who qualifies as a New Investigator under this opportunity?

The New Investigator category is intended for independent investigators within 10 years of their first faculty appointment (or equivalent). New Investigator applicants must also meet specific eligibility criteria described in the funding announcement.

12) Do New Investigators compete directly against established investigators?

No. New Investigators compete in a separate pool from established investigators during both peer review and programmatic review.

13) Are New Investigators encouraged to include collaborators?

Yes. New Investigators are strongly encouraged to collaborate with experienced lung cancer researchers and/or other experts who bring needed capabilities (for example, clinical lung cancer insight, advanced computational methods, exposure science, imaging, or specialized model systems).

14) What must be explained about collaborations in a New Investigator application?

The application must clearly explain how collaborations fill gaps in the principal investigator's background and strengthen the project’s ability to answer the research question.

15) Is military health relevance required?

Yes. A defining feature of the opportunity is the requirement to demonstrate relevance to military health. Projects are expected to connect in a meaningful way to the needs of Service Members, Veterans, and their families (Military Health System beneficiaries).

16) How can an applicant demonstrate military health relevance?

The announcement encourages applicants to demonstrate relevance through concrete elements such as using military or Veteran populations, biospecimens, or databases; partnering with Department of Defense or Department of Veterans Affairs investigators; or addressing lung cancer factors particularly pertinent to military communities.

17) Does the opportunity recognize non-tobacco environmental exposures relevant to the military?

Yes. The announcement specifically notes that military health relevance can include environmental exposures other than tobacco, recognizing that military-related exposures and service-connected contexts may shape lung cancer risk, biology, detection, or care needs.

18) Who is the sponsoring agency and what is the opportunity number?

The funding opportunity is offered by the Department of Defense (Department of the Army, USAMRAA) under opportunity number W81XWH-22-LCRP-IDA.

19) What type of funding instrument may be used?

The posting indicates the opportunity may be supported through either grants or cooperative agreements.

20) What is the stated eligibility for this opportunity?

Eligibility is described as unrestricted (open to any type of entity), subject to any clarifications in the funding announcement.

21) How many awards were anticipated for this FY22 cycle?

The posting indicated an anticipated total of about 12 awards.

22) What was the application closing date listed for this FY22 cycle?

The original application closing date listed for this FY22 cycle was July 27, 2022.

23) What is the CFDA number associated with this opportunity?

The opportunity is associated with CFDA number 12.420.

24) Is this a discretionary funding opportunity?

Yes. It is listed as a discretionary opportunity.